In a series of studies utilizing mouse models of colorectal cancer, the employment of CCR2 antagonists (e.g., RS504393, RS102895) or the suppression of the CCL2/CCR2 axis has been demonstrated to result in a substantial reduction in the infiltration of TAMs within tumors (138, 139). This evidence concerns the gene CCR2 and colorectal cancer.